MiR-106b promotes therapeutic antibody expression in CHO cells by targeting deubiquitinase CYLD
- 93 Downloads
MicroRNAs (miRNAs) function as important regulators of major cellular processes, such as cell cycle, proliferation, development, and apoptosis. Recently, miRNA engineering of Chinese hamster ovary (CHO) cells has emerged as a promising strategy for enhancing therapeutic antibody production. Previously, we have reported that inhibition of deubiquitinase cylindromatosis (CYLD) remarkably enhanced the therapeutic antibody production in CHO cells. However, the mechanisms regulating CYLD in CHO cells remain elusive. Herein, we demonstrated that miR-106b targets CYLD directly, as shown by a series of bioinformatics analyses and experimental assays. Stable overexpression of miR-106b in CHO cells promoted CHO cell viability and subsequent antibody expression in transient transfection assay. Furthermore, the results in fed-batch culture showed that stable overexpression of miR-106b in a CHO-IgG cell line achieved about 0.66-fold promotion in product titer compared to the parental cells. Meanwhile, overexpression of miR-106b did not affect the quality of antibody. Taken together, our findings highlight the effect of miR-106b inhibition in CYLD synthesis and its function in antibody expression as a new target for improving CHO manufacturing cells.
KeywordsmiR-106b CYLD CHO cells Therapeutic antibody Cell engineering
This work was supported by the National Natural Science Foundation of China (Grants 31600749), the Initial Foundation of Doctoral Scientific Research in Anhui University (Y01001487), the Key Research and Development Projects in Anhui Province (1704a07020075), and the project in Biotechnical Research Centre for Anhui Tianxiang Cereals, Oils and Food stuffs Co., Ltd., Anhui University (Y06159202).
Compliance with ethical standards
The authors declare that they have no conflicts of interest.
This study does not involve any human participants or animals.
- De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13(2):97–110 doi: https://doi.org/10.1038/nrc3447
- Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J, Rodilla V, Ingles-Esteve J, Nomdedeu J, Bellosillo B, Besses C, Abdel-Wahab O, Kucine N, Sun SC, Song G, Mullighan CC, Levine RL, Rajewsky K, Aifantis I, Bigas A (2010) The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 18(3):268–281. https://doi.org/10.1016/j.ccr.2010.08.006 CrossRefGoogle Scholar
- Fei SJ, Zhang XC, Dong S, Cheng H, Zhang YF, Huang L, Zhou HY, Xie Z, Chen ZH, Wu YL (2013) Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells. PLoS One 8(7):e69104. https://doi.org/10.1371/journal.pone.0069104 CrossRefGoogle Scholar
- Fischer S, Marquart KF, Pieper LA, Fieder J, Gamer M, Gorr I, Schulz P, Bradl H (2017) miRNA engineering of CHO cells facilitates production of difficult-to-express proteins and increases success in cell line development. Biotechnol Bioeng 114(7):1495–1510. https://doi.org/10.1002/bit.26280 CrossRefGoogle Scholar
- Fischer S, Paul AJ, Wagner A, Mathias S, Geiss M, Schandock F, Domnowski M, Zimmermann J, Handrick R, Hesse F, Otte K (2015) miR-2861 as novel HDAC5 inhibitor in CHO cells enhances productivity while maintaining product quality. Biotechnol Bioeng 112(10):2142–2153. https://doi.org/10.1002/bit.25626 CrossRefGoogle Scholar
- Jono H, Lim JH, Chen LF, Xu H, Trompouki E, Pan ZK, Mosialos G, Li JD (2004) NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J Biol Chem 279(35):36171–36174. https://doi.org/10.1074/jbc.M406638200 CrossRefGoogle Scholar
- Li BS, Zuo QF, Zhao YL, Xiao B, Zhuang Y, Mao XH, Wu C, Yang SM, Zeng H, Zou QM, Guo G (2015) MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival. Oncogene 34(20):2556–2565. https://doi.org/10.1038/onc.2014.214 CrossRefGoogle Scholar
- Ni F, Zhao H, Cui H, Wu Z, Chen L, Hu Z, Guo C, Liu Y, Chen Z, Wang X, Chen D, Wei H, Wang S (2015) MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma. Cancer Lett 356(2 Pt B):809–818. https://doi.org/10.1016/j.canlet.2014.10.041 CrossRefGoogle Scholar
- Ni T, Li XY, Lu N, An T, Liu ZP, Fu R, Lv WC, Zhang YW, Xu XJ, Grant Rowe R, Lin YS, Scherer A, Feinberg T, Zheng XQ, Chen BA, Liu XS, Guo QL, Wu ZQ, Weiss SJ (2016) Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer. Nat Cell Biol 18(11):1221–1232. https://doi.org/10.1038/ncb3425 CrossRefGoogle Scholar
- Xu C, He X, Zheng Z, Zhang Z, Wei C, Guan K, Hou L, Zhang B, Zhu L, Cao Y, Zhang Y, Cao Y, Ma S, Wang P, Zhang P, Xu Q, Ling Y, Yang X, Zhong H (2014) Downregulation of microRNA miR-526a by enterovirus inhibits RIG-I-dependent innate immune response. J Virol 88(19):11356–11368. https://doi.org/10.1128/JVI.01400-14 CrossRefGoogle Scholar
- Xu DD, Zhou PJ, Wang Y, Zhang L, Fu WY, Ruan BB, Xu HP, Hu CZ, Tian L, Qin JH, Wang S, Wang X, Li YC, Liu QY, Ren Z, Zhang R, Wang YF (2016) Reciprocal activation between STAT3 and miR-181b regulates the proliferation of esophageal cancer stem-like cells via the CYLD pathway. Mol Cancer 15(1):40. https://doi.org/10.1186/s12943-016-0521-7 CrossRefGoogle Scholar
- Ye H, Liu X, Lv M, Wu Y, Kuang S, Gong J, Yuan P, Zhong Z, Li Q, Jia H, Sun J, Chen Z, Guo AY (2012) MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res 40(12):5201–5214. https://doi.org/10.1093/nar/gks175 CrossRefGoogle Scholar